A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors

Summary

This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb20717, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb20717 in subjects with selected advanced solid tumors.

Timeline

Start

2018-07-10

Primary completion

2022-06-01

Completion

2022-09-06

Drugs

Indications